Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by StoneRidge PMG Advisors LLC

StoneRidge PMG Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 804 shares of the biopharmaceutical company’s stock, valued at approximately $610,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Orbimed Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $11,358,000. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $5,682,636,000. Contravisory Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $6,327,000. Oxbow Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $3,342,000. Finally, Compass Financial Management LLC grew its position in Regeneron Pharmaceuticals by 4,526.2% during the third quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock worth $2,280,000 after buying an additional 2,942 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 7,439 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total value of $7,219,251.94. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,652,693.38. This represents a 81.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 27,028 shares of company stock worth $25,025,950. 6.97% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. Citigroup upped their target price on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a research note on Friday, October 30th. Truist Financial lifted their price target on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Bank of America boosted their price objective on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Finally, Robert W. Baird increased their price target on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $904.35 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The firm has a market cap of $93.11 billion, a P/E ratio of 19.97, a P/E/G ratio of 1.20 and a beta of 0.10. The business’s 50 day moving average price is $804.38 and its 200-day moving average price is $742.81.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the prior year, the company earned $11.83 earnings per share. The firm’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.